These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25007352)

  • 1. Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil.
    Urbanowicz T; Straburzyńska-Migaj E; Katyńska I; Araszkiewicz A; Oko-Sarnowska Z; Grajek S; Jemielity M
    Ann Transplant; 2014 Jul; 19():325-30. PubMed ID: 25007352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide.
    Lepore JJ; Maroo A; Bigatello LM; Dec GW; Zapol WM; Bloch KD; Semigran MJ
    Chest; 2005 May; 127(5):1647-53. PubMed ID: 15888841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
    Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
    Guazzi M; Vicenzi M; Arena R
    Eur J Heart Fail; 2012 Jan; 14(1):82-90. PubMed ID: 22067410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of resolution of pulmonary hypertension, long-term allograft right ventricular function, and exercise capacity in high-risk heart transplant recipients listed under oral sildenafil.
    De Santo LS; Buonocore M; Agrusta F; Bancone C; Galdieri N; Romano G; Maiello C; Amarelli C
    Clin Transplant; 2014 Jul; 28(7):837-43. PubMed ID: 24828060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
    Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
    Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?
    Madden BP; Sheth A; Wilde M; Ong YE
    Vascul Pharmacol; 2007; 47(2-3):184-8. PubMed ID: 17627899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil is more selective pulmonary vasodilator than prostaglandin E1 in patients with pulmonary hypertension due to heart failure.
    Al-Hiti H; Melenovský V; Syrovátka P; Kettner J; Málek I; Kautzner J
    Physiol Res; 2011; 60(2):303-8. PubMed ID: 21114369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease.
    Humpl T; Reyes JT; Erickson S; Armano R; Holtby H; Adatia I
    Cardiol Young; 2011 Apr; 21(2):187-93. PubMed ID: 21138617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure.
    Freitas AF; Bacal F; Oliveira Jde L; Santos RH; Moreira LF; Silva CP; Mangini S; Carneiro RM; Fiorelli AI; Bocchi EA
    Arq Bras Cardiol; 2009 Feb; 92(2):116-26. PubMed ID: 19360244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.
    Michelakis E; Tymchak W; Lien D; Webster L; Hashimoto K; Archer S
    Circulation; 2002 May; 105(20):2398-403. PubMed ID: 12021227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects.
    Raja SG; Danton MD; MacArthur KJ; Pollock JC
    J Cardiothorac Vasc Anesth; 2007 Apr; 21(2):203-7. PubMed ID: 17418732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension.
    Leuchte HH; Schwaiblmair M; Baumgartner RA; Neurohr CF; Kolbe T; Behr J
    Chest; 2004 Feb; 125(2):580-6. PubMed ID: 14769741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the Montréal Heart Institute.
    Potter BJ; White M; Carrier M; Pellerin M; L'Allier PL; Pelletier GB; Racine N; Ducharme A
    Can J Cardiol; 2012; 28(1):69-73. PubMed ID: 22129489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.